ESMO: Padcev/Keytruda Combo Edges Closer To First-Line Bladder Cancer Filing

The chances of the much-touted combination of Seagen Inc./Astellas Pharma, Inc.'s Padcev and Merck & Co., Inc.'s Keytruda getting approval in first-line urothelial cancer would appear to have improved on the back of more positive data presented at the European Society for Medical Oncology conference in Paris.

Cohort K of the Phase Ib/II EV-103/KEYNOTE-869 trial compared a combination of the antibody-drug conjugate Padcev (enfortumab vedotin) and the anti-PD-1 immunotherapy Keytruda (pembrolizumab) in first-line unresectable locally advanced or...